BCRX
$9.21
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
Intraday
Recent News
BioCryst (BCRX) Soars 13% on Acquisition Buzz
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) is one of the 10 Stocks Worth Watching Right Now. BioCryst snapped a three-day losing streak on Monday, jumping 13.14 percent to finish at $9.30 apiece, as investors loaded portfolios amid rumors that it is set to be acquired by a large-cap biopharmaceutical company. Murmurs about the supposed acquisition broke out […]
BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On March 2, Wedbush analyst Laura Chico increased the firm’s price target on BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) to $22 from $21. The analyst maintained her Outperform rating on the stock. Although the company had previously preannounced […]
BioCryst Pharmaceuticals Conference: Profitability Pivot, ORLADEYO Growth, Navenibart Phase 3 Timeline
BioCryst Pharmaceuticals (NASDAQ:BCRX) executives highlighted the company’s transition to profitability, continued growth of its hereditary angioedema (HAE) franchise, and progress on newly acquired and earlier-stage pipeline programs during a recent investor discussion hosted by a biotech team. Re
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Net Income Turns Positive And Astria Deal Expands HAE Portfolio
BioCryst Pharmaceuticals (BCRX) just hit an inflection point, reporting its first full year of net income on the back of higher revenue, expanding operating profit and stronger uptake of hereditary angioedema treatment ORLADEYO. See our latest analysis for BioCryst Pharmaceuticals. The strong earnings surprise, first full year of net income and the Astria Therapeutics acquisition have gone hand in hand with powerful momentum, with a 1 month share price return of 32.98% and a 90 day gain of...
BioCryst’s First Profitable Year Recasts Hereditary Angioedema Growth Story
BioCryst Pharmaceuticals (NasdaqGS:BCRX) reported its first full year of profitability, supported by commercial traction for ORLADEYO. The company acquired Astria Therapeutics, adding a late stage hereditary angioedema therapy and a pediatric FDA approved asset to its portfolio. These moves reshape BioCryst's hereditary angioedema franchise and mark a new phase for the business. BioCryst, trading at around $8.75, has seen its share price move 17.4% over the past week and 33.0% over the past...